GC Biopharma Corp. (KRX: 006280)
South Korea
· Delayed Price · Currency is KRW 138,600
-1,500 (-1.07%)
Nov 15, 2024, 3:30 PM KST
GC Biopharma Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 1,618,467 | 1,626,644 | 1,711,313 | 1,537,826 | 1,504,115 | 1,357,117 | Upgrade
|
| Other Revenue | -0 | -0 | -0 | -0 | - | - | Upgrade
|
| Revenue | 1,618,467 | 1,626,644 | 1,711,313 | 1,537,826 | 1,504,115 | 1,357,117 | Upgrade
|
| Revenue Growth (YoY) | -2.12% | -4.95% | 11.28% | 2.24% | 10.83% | 1.67% | Upgrade
|
| Cost of Revenue | 1,160,569 | 1,143,313 | 1,131,350 | 1,018,585 | 1,064,691 | 986,121 | Upgrade
|
| Gross Profit | 457,899 | 483,331 | 579,962 | 519,240 | 439,425 | 370,996 | Upgrade
|
| Selling, General & Admin | 256,975 | 258,898 | 292,484 | 282,771 | 242,918 | 193,868 | Upgrade
|
| Research & Development | 155,205 | 173,487 | 191,347 | 146,030 | 137,987 | 126,673 | Upgrade
|
| Other Operating Expenses | 1,370 | 1,624 | 2,165 | 1,594 | 1,259 | 1,160 | Upgrade
|
| Operating Expenses | 431,455 | 449,420 | 499,253 | 445,515 | 389,239 | 329,307 | Upgrade
|
| Operating Income | 26,443 | 33,911 | 80,710 | 73,726 | 50,186 | 41,690 | Upgrade
|
| Interest Expense | -35,286 | -28,483 | -18,393 | -12,501 | -10,354 | -9,609 | Upgrade
|
| Interest & Investment Income | 3,000 | 3,421 | 3,785 | 1,665 | 1,555 | 2,320 | Upgrade
|
| Earnings From Equity Investments | - | - | 40,467 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 1,885 | 1,010 | 2,570 | 13,477 | -17,517 | 985.39 | Upgrade
|
| Other Non Operating Income (Expenses) | -878.6 | 3,147 | -4,842 | 8,002 | -913.65 | -13,750 | Upgrade
|
| EBT Excluding Unusual Items | -4,836 | 13,006 | 104,296 | 84,368 | 22,956 | 21,636 | Upgrade
|
| Gain (Loss) on Sale of Investments | -43,476 | -37,222 | -18,759 | 81,200 | 31,038 | -9,886 | Upgrade
|
| Gain (Loss) on Sale of Assets | -3,649 | -2,919 | 190 | 6,991 | 58,619 | 853 | Upgrade
|
| Asset Writedown | -8 | - | - | - | -8,140 | -13,887 | Upgrade
|
| Other Unusual Items | -190 | - | - | - | - | 121 | Upgrade
|
| Pretax Income | -52,159 | -27,135 | 85,728 | 172,559 | 104,474 | -1,163 | Upgrade
|
| Income Tax Expense | -12,050 | -7,326 | 16,313 | 35,609 | 15,366 | 5,146 | Upgrade
|
| Earnings From Continuing Operations | -40,109 | -19,809 | 69,415 | 136,950 | 89,108 | -6,309 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | - | 162.96 | -4,979 | Upgrade
|
| Net Income to Company | -40,109 | -19,809 | 69,415 | 136,950 | 89,271 | -11,287 | Upgrade
|
| Minority Interest in Earnings | 1,913 | -6,823 | -3,962 | -13,738 | -8,222 | 7,650 | Upgrade
|
| Net Income | -38,195 | -26,632 | 65,453 | 123,212 | 81,049 | -3,638 | Upgrade
|
| Net Income to Common | -38,195 | -26,632 | 65,453 | 123,212 | 81,049 | -3,638 | Upgrade
|
| Net Income Growth | - | - | -46.88% | 52.02% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 11 | 11 | 11 | 5 | 11 | 11 | Upgrade
|
| Shares Outstanding (Diluted) | 11 | 11 | 11 | 5 | 11 | 11 | Upgrade
|
| Shares Change (YoY) | - | - | 125.85% | -55.72% | - | - | Upgrade
|
| EPS (Basic) | -3346.58 | -2333.42 | 5734.87 | 24381.79 | 7101.34 | -318.72 | Upgrade
|
| EPS (Diluted) | -3347.42 | -2333.42 | 5734.87 | 24381.79 | 7101.34 | -318.72 | Upgrade
|
| EPS Growth | - | - | -76.48% | 243.34% | - | - | Upgrade
|
| Free Cash Flow | -115,346 | -84,560 | 61,158 | 23,658 | -46,902 | -87,163 | Upgrade
|
| Free Cash Flow Per Share | -10106.35 | -7408.97 | 5358.56 | 4681.52 | -4109.46 | -7637.06 | Upgrade
|
| Dividend Per Share | 1500.000 | 1500.000 | - | - | - | - | Upgrade
|
| Gross Margin | 28.29% | 29.71% | 33.89% | 33.76% | 29.21% | 27.34% | Upgrade
|
| Operating Margin | 1.63% | 2.08% | 4.72% | 4.79% | 3.34% | 3.07% | Upgrade
|
| Profit Margin | -2.36% | -1.64% | 3.82% | 8.01% | 5.39% | -0.27% | Upgrade
|
| Free Cash Flow Margin | -7.13% | -5.20% | 3.57% | 1.54% | -3.12% | -6.42% | Upgrade
|
| EBITDA | 105,312 | 109,810 | 145,806 | 129,630 | 98,977 | 88,356 | Upgrade
|
| EBITDA Margin | 6.51% | 6.75% | 8.52% | 8.43% | 6.58% | 6.51% | Upgrade
|
| D&A For EBITDA | 78,868 | 75,899 | 65,096 | 55,904 | 48,791 | 46,666 | Upgrade
|
| EBIT | 26,443 | 33,911 | 80,710 | 73,726 | 50,186 | 41,690 | Upgrade
|
| EBIT Margin | 1.63% | 2.08% | 4.72% | 4.79% | 3.34% | 3.07% | Upgrade
|
| Effective Tax Rate | - | - | 19.03% | 20.64% | 14.71% | - | Upgrade
|
| Advertising Expenses | - | 40,739 | 50,726 | 49,015 | 39,770 | 26,253 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.